SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close. SCYNEXIS announced the achievement of the first development milestone of …